Table 1.
Clinical and demographic baseline data of the exploration cohort
| Clinical characteristics | Prevalence (n = 114) |
|---|---|
| Anti-AChR-Ab positive, n (%) | 114 (100%) |
| Gender, n (%) | |
| Female | 53 (46.5%) |
| Male | 61 (53.5%) |
| Age (years), median (IQR) | 60 (30) |
| Onset, n (%) | |
| Early onset | 60 (52.6%) |
| Late onset | 54 (47.4%) |
| Thymoma, n (%) | |
| No thymoma | 104 (91.2%) |
| Thymoma | 10 (8.7%) |
| QMG score, median (IQR) | |
| Baselinea | 6 (7) |
| After 12 months | 5 (8.75) |
| MG-ADL score, median (IQR) | |
| Baselinea | 3 (5) |
| After 12 months | 3 (5.25) |
| Treatment, n (%) | |
| Treatment naïve | 28 (24.6%) |
| Standard IST | 86 (75.4%) |
| Prednisolone | 5 (4.4%) |
| Azathioprine | 69 (60.5%) |
| Methotrexate | 7 (6.1%) |
| Mycophenolate-mofetil | 5 (4.4%) |
| Prednisolone dose/day, median (IQR) | 5 (8) |
AChR acetylcholine receptor, Ab antibody, IQR interquartile range, IST immunosuppressive therapy, MG-ADL myasthenia gravis activities of daily living; no., number, QMG quantitative myasthenia gravis
aBaseline was defined as the time of blood sampling